Combined dna vaccine and biological modifiers for cancer therapy
AssigneeInstitut National de la Sante et de la Recherche Medicale
InventorsRose Padua, Christine Chomienne, Dominique Charron
Life of this patent
Estimating the term…
Abstract
The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well as specific nucleic acid constructs that are particularly suitable for the preparation of such compositions.
Claims24
A vaccine composition comprising (i) a non-immunosuppressive inducer of tumor cell apoptosis and (ii) a nucleic acid comprising a sequence that encodes an immunogenic polypeptide, in a pharmaceutically acceptable carrier.
An isolated nucleic acid that comprises (a) a sequence that encodes a PML-RARα antigen and further comprises (b) a sequence that encodes a polypeptide that enhances the immune response to said PML-RARα antigen.
An isolated nucleic acid comprising the sequence SEQ ID no10.
A kit comprising (i) a first pharmaceutical composition that comprises a non-immunosuppressive inducer of tumor cell apoptosis and (ii) a second pharmaceutical composition that comprises a nucleic acid comprising a sequence that encodes an immunogenic polypeptide.
Dependencies are inferred from the claim text.